C4 Therapeutics (CCCC) AGM 2026 summary

Opening remarks and agenda

• Meeting called to order with board members, executive management, and independent auditors present.

• Four proposals outlined for consideration, as detailed in the proxy statement.

• Shareholder list and quorum confirmed, with over 50% of voting stock represented.

Board and executive committee updates

• Class III director nominees for terms expiring at the 2029 annual meeting were presented: Andrew Hirsch, Stephen Fawell, and Utpal Koppikar.

Shareholder proposals

• Four proposals included: election of directors, advisory vote on executive compensation, ratification of KPMG LLP as auditor, and amendment to the 2020 Stock Option and Incentive Plan.

• No other nominations or business proposals were received.